Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Stifel Downgrades Spire to Hold, Raises Price Target to $75

Stifel Downgrades Spire to Hold, Raises Price Target to $75

Stifel analyst Selman Akyol downgrades Spire (NYSE:SR) from Buy to Hold and raises the price target from $73 to $75.

byBenzinga Newsdesk

February 7, 2023

1 minute read

Stifel analyst Selman Akyol downgrades Spire (NYSE:SR) from Buy to Hold and raises the price target from $73 to $75.

Analyst Ratings

Expert Ratings For Mastercard

By Benzinga Insights

February 1, 3:00 PM

Analysts’ ratings for Mastercard (NYSE:MA) over the last quarter vary from bullish to bearish, as provided by 13…

Erasca Q3 EPS $(0.29) Up From $(0.46) YoY

By Benzinga Newsdesk

November 9, 5:50 PM

Erasca (NASDAQ:ERAS) reported quarterly losses of $(0.29) per share. This is a 36.96 percent increase over losses of $(0.46) per share from the same period last year.

ERAS

Benzinga’s Top Ratings Upgrades, Downgrades For September 22, 2023

By Benzinga Insights

September 22, 11:00 AM

Upgrades For Agile Therapeutics Inc (NASDAQ:AGRX), Maxim Group upgraded the previous rating of Hold to Buy. For the…

AGRX

Denali Therapeutics Breakthrough Blood-Brain Barrier Platform A Game-Changer in Neurodegenerative Diseases: Analyst

By Vandana Singh

September 6, 2:45 PM

B Riley Securities initiated coverage on Denali Therapeutics Inc (NASDAQ: DNLI) with a Buy rating and a

BIIB

Stifel Downgrades Spire to Hold, Raises Price Target to $75

Related Posts

Expert Ratings For Mastercard

Erasca Q3 EPS $(0.29) Up From $(0.46) YoY

Benzinga’s Top Ratings Upgrades, Downgrades For September 22, 2023

Denali Therapeutics Breakthrough Blood-Brain Barrier Platform A Game-Changer in Neurodegenerative Diseases: Analyst